InMed Pharmaceuticals (INM) Operating Margin (2021 - 2025)
InMed Pharmaceuticals (INM) reported Operating Margin of 256.36% for Q4 2025, down 5360.0% on a YoY basis from 4.87% in Q4 2024, and down 57.72% quarter-over-quarter from 162.54% in Q3 2025.
InMed Pharmaceuticals (INM) Operating Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Operating Margin for 5 years, with the latest figure at 256.36% in Q4 2025.
- For the quarter ending Q4 2025, Operating Margin fell 5360.0% year-over-year to 256.36%; the trailing twelve-month figure through Dec 2025 stood at 184.16% (down 2134.0% YoY), and the FY2025 full-year result was 160.77%, up 1750.0% from the prior year.
- Operating Margin for Q4 2025 stood at 256.36%, down from 162.54% in the prior quarter.
- The five-year high for Operating Margin was 20.99% in Q2 2023, with the low at 1626.64% in Q4 2021.
- Historically, Operating Margin has averaged 452.69% across 5 years, with a median of 202.75% in 2024.
- Annual changes were most pronounced in 2023 — Operating Margin jumped 124562 bps — and 2024, when it slumped 13755 bps.
- InMed Pharmaceuticals' Operating Margin stood at 1626.64% in 2021, then jumped by 71 bps to 471.26% in 2022, then jumped by 72 bps to 132.64% in 2023, then sank by 53 bps to 202.75% in 2024, then slipped by 26 bps to 256.36% in 2025.
- The last three Operating Margin figures came in at 256.36% (Q4 2025), 162.54% (Q3 2025), and 189.17% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -122.23% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -12.88% |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -256.36% |
| Sep 30, 2025 | -162.54% |
| Jun 30, 2025 | -189.17% |
| Mar 31, 2025 | -151.24% |
| Dec 31, 2024 | -202.75% |
| Sep 30, 2024 | -137.19% |
| Jun 30, 2024 | -158.54% |
| Mar 31, 2024 | -157.28% |
| Dec 31, 2023 | -132.64% |
| Sep 30, 2023 | -296.37% |
| Jun 30, 2023 | -20.99% |
| Mar 31, 2023 | -208.13% |
| Dec 31, 2022 | -471.26% |
| Sep 30, 2022 | -1,114.75% |
| Jun 30, 2022 | -1,266.61% |
| Mar 31, 2022 | -1,143.35% |
| Dec 31, 2021 | -1,626.64% |